bolstered evidence that, after a short course of neoadjuvant endocrine therapy (NET), an on-treatment Ki-67 index can identify patients who can be spared intensive chemotherapy in the adjuvant setting.3
“This was the pivotal trial [TROPION- Lung01] in which patients who initially received chemotherapy and immune therapy were randomly assigned to receive Dato-DXd vs docetaxel,” Johnson said. “At the end of the day, the overall survival was negative for this group of pa...
Nurses, Talk AEs, Interstitial Lung Disease, Before Treating With T-DXd Advancing the Standard of Breast Cancer Treatment With CDK4/6 Inhibitors Pattie Jakel Highlights the Challenges With Oral Therapies in Breast Cancer Kara Morris and Christin...
In the next 1 to 3 years, there’s going to be a slew of neoadjuvant and adjuvant immunotherapy studies maturing that will be exciting to think about how to incorporate hopefully positive results into our standard treatment paradigm. There’s still some work to do in the post-osimertinib se...
The identification of new biomarkers and molecular signatures is leading to development of new therapeutic strategies including immunotherapy, targeted therapy and antibody-drug conjugates (ADCs). Against a background where chemotherapy has always been considered the standard of care, evolution towards a ...
Antibody-drug conjugates: Smart chemotherapy delivery across tumor histologies. CA Cancer J Clin 2022;72:165-82. [21]Jerusalem G, Park YH, Yamashita T, et al. Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis. ...
The Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for ribociclib in August 2016 and has also accepted a New Drug Application (NDA) and granted priority review for ribociclib as firstline treatment of postmenopausal women with HR+/HER2- advanced or metastatic bre...
The discussion on NSCLC narrowed in on findings from recent clinical trials, particularly involving a combination regimen of amivantamab plus lazertinib vs osimertinib and chemotherapy. FDA Approves Dato-DXd in Metastatic HR+/HER2– Breast Cancer Russ Conroy January 18th 2025 Article Data from the ...
That [approval] set a really significant milestone in TNBC, as it was the first nonchemotherapy drug that was approved for this patient population. We're also seeing a great deal of activity with new classes of drugs, including antibody-drug conjugates; there are several of them that are in...
“Trastuzumab deruxtecan is the first HER2-targeted therapy to demonstrate statistically significant and clinically meaningful improvement in PFS and OS compared [with] standard chemotherapy for patients with HER2-low metastatic breast cancer,” said lead author Shanu Modi, MD, who is a medical oncol...